The FTA-ABS test is a blood test to detect antibodies to the bacteria Treponema pallidum, which causes syphilis.
This test is used to confirm whether a positive screening test for syphilis means there is a true infection.
A blood sample is needed. For information on how this is done, see: Venipuncture
No special preparation is necessary.
When the needle is inserted to draw blood, you may feel moderate pain, or only a prick or stinging sensation. Afterward, there may be some throbbing.
This test is routinely done to confirm whether a positive screening test for syphilis (either VDRL or RPR) means you have a current syphilis infection.
It may also be done when other syphilis tests are negative, to rule out a possible false-negative result.
A negative or nonreactive result means there you do not have a current or past infection with syphilis.
Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples. Talk to your doctor about the meaning of your specific test results.
A positive FTA-ABS is usually a sign of a syphilis infection. This test result will remain positive for life even if syphilis has been adequately treated. Therefore, it cannot be used to monitor the treatment of syphilis.
Other illnesses such as yaws and pinta may also result in positive FTA-ABS results. Occasionally there can be a false positive result, most often in women with lupus.
Veins and arteries vary in size from one patient to another and from one side of the body to the other. Obtaining a blood sample from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight but may include:
Fluorescent treponemal antibody absorption test
Tramont EC. Treponema pallidum (syphilis). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap 238.
Updated by: Linda J. Vorvick, MD, Medical Director, MEDEX Northwest Division of Physician Assistant Studies, University of Washington, School of Medicine; Jatin M. Vyas, MD, PhD, Assistant Professor in Medicine, Harvard Medical School; Assistant in Medicine, Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2012, A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.